Summary.-ICRF 159 and Triton WR 1339 have been examined for their ability to suppress subcutaneous growth and pulmonary metastases from a transplanted rat epithelioma. Neither compound influenced subcutaneous tumour development or reduced the propensity to metastasize when administered in regimens reported to suppress pulmonary, lymph node or intracerebral metastases in other experimental systems.
Summary.-ICRF 159 and Triton WR 1339 have been examined for their ability to suppress subcutaneous growth and pulmonary metastases from a transplanted rat epithelioma. Neither compound influenced subcutaneous tumour development or reduced the propensity to metastasize when administered in regimens reported to suppress pulmonary, lymph node or intracerebral metastases in other experimental systems.
A NUAIBER of chemotherapeutic agents have recently been investigated for their selective inhibition of metastases from experimental animal ttimours (reviewe(d by Garattini and Franchi, 1973) . The objective of the present investigation was to assess the anti-metastatic effect of two compounds, ICRF 159 and Triton WR 1339, on the development of pulmonary metastases from a syngeneically transplanted rat epithelioma. Both of these compounds have been reported as having potential anti-metastatic effects in other animals studies, although they are thought to have widely differenit modes of action.
ICRF 159 [(± )-l,2-bis(3-5-dioxopiperazin-1-yl)propane] has been reported to inhibit selectively the development of pulmonary metastases from subcutaneous or intramuscular grafts of the Lewis lung carcinoma in C57B I mice (Salsbury, Buirrage and Hellmann, 1970; Hellman and Burrage, 1969; Franchi and Garattini, 1.973) . Althouigh a powerful anti-mitotic (Sandberg and Goldin, 1971) (Salsbury et al., 1970; Le Serve and Hellmann, 1972) . The presence in ICRF 159 treated animals of a well formed vasculature between tumour cells and blood has been interpreted as the main factor in preventing haematogenous tumour spread (Salsbury et al., 1970; Hellmann et al., 1973) . The clinical application of ICRF 159 to the treatment of acute leukaemia and lymphosarcoma has been described (Hellmann et al., 1969) , although the beneficial effects reported in these cases were interpreted as due to the drug's anti-mitotic action.
Triton WR 1339 (polyoxyethylene ether of formaldehyde polymers of acetylphenol) a non-ionic surfactant, has been reported to modify metastasis in a number of experimental systenms, with no influence on the growth of initial tumour implants. Thus, WR 1339 treatment suppresses the formation of pulmonary metastases from intramuscuilar grafts of the Lewis lung carcinoma (Franchi et al., 1971; Garattini, 1971, 1973) , lymph node metastases from intratibial transplants of Ehrlich carcinoma (Rosso et al., 1969; Franchi et al., 1971) and pulmonary nietastasis of intracerebral implants of sarcoma 180 or Ehrlich carcinoma in Swiss mice (Rosso et a., 1969; Franchi et al., 1971) . Enhancement of metastases has, however, been reported with other animal tumours treated with Triton WR 1339. With a transplanted metastasizing lymphoma in hamsters, Triton WR 1339 treatment reduced the growth of initial tumour inocula but increased the propensity to metastasize, particularly to the liver (Carter, Birbeck and Stock, 1971; Cotmore and Carter, 1973) . In addition, the compouild increases the formation of metastases from intracaecal implantations of tumours in the mouse (Franchi and Garattini, 1973) .
The biological effects of Triton WR 1339 are complex, involving enhancement of the reticuloendothelial system, with activation of macrophage lysosomes (Franchi and Garattini, 1973; Franchi et al., 1971) . Its anti-metastatic effects are thought to be due to binding to tumour cell surfaces, altering their movement and potential for attachment, and thus facilitating host recognition and destruction of cells liberated from the initial tumour mass (Francbi et al., 1971; Franchi and Garattini, 1973; Morasca, 1973) . The compound does not influence the growth of tumour cells already lodged in other organs (Franchi et al., 1971) .
In the present studies, the ability of these two compounds to influence the development of spontaneous pulmonary metastases from a subcutaneously transplanted rat epithelioma has been investigated. This tumour is currently being used to explore immunotherapeutic techniques for the control of metastases (Baldwin and Pimm, 1973) , and the results of the present studies are compared and contrasted with those achieved by immunotherapy.
MATERIALS AND METHODS
Epitheliomia Spl. Epithelioma SpI arose spontaneously in a female rat in the inbred Wistar strain of the department, and was maintained by subcutaneous transplantation in syngeIneic female rats. In the present a studies, the tumour was in its 32-36th transplant generation. This tumour regularly produces pulmonary metastases from subcutaneous grafts (Baldwin, 1966; Baldwin and Pimm, 1973 (Wexler, 1966) . The numbers of macroscopically visible lung surface nodules were counted. When the number of nodules was greater than 200 the result was scored as 200+. Each experiment was terminated when the majority of animals exhibited respiratory distress, due to pulmonary metastases, or when subcutaneous tumours had reached 3-4 cm diameter. Table I shows the influence of ICRF 500 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 17, 18 ,19, 20 In the second test, rats were treated with a total of 5000 mg/kg body weight of Triton WR 1339, either as 10 injections of 500 mg/kg or 4 injections of 1250 mg/kg. Again, however, neither treatment influenced the growth of subcutaneous tumours or significantly altered the numbers of pulmonary metastases.
RESULTS

ICRF 159
In a final test, in addition to repeated administration of Triton WR 1339 throughout the entire course of the experiment, rats were treated by surgical removal of subcutaneously growing tumour grafts 11 days after their implantation. In this case there was statistically significant enhancement of pulmonary metastases. Thus, 5/5 treated rats developed 73-200 Hellmann and Burrage (1969) to suppress the development of pulmonary metastases from subcutaneous grafts of the Lewis lung carcinoma, where injection of the compound during the first or second 7 days after tumour implantation eliminaged metastases almost completely. In addition, treatment of mice with 9 doses of only 7 5 mg/kg were reported to partially restrict metastases from the Lewis lung carcinoma (Franchi and Garattini, 1973) .
In the present studies, prolonged administration of the drug (12 x 30 mg/kg) to rats with epithelioma Sp 1 grafts did not influence the eventual metastases in these animals. With the Lewis lung carcinoma, the suppression of metastases by ICRF 159 is caused by failure of tumour cells to enter the blood from the initial tumour graft, since no circulating malignant cells are found in drug treated mice, in comparison with untreated animals (Salsbury et al., 1970) . In the present studies, however, chemotherapy with ICRF 159 in conjunction with surgical excision of epithelioma Sp 1 grafts failed to restrict the development of pulmonary metastases. In this case tumour grafts were excised one day after the administration of ICRF 159 had ended.
Thus, metastases ultimately found in these rats could not have been formed by tumour cells allowed to enter the blood after the drug had been withdrawn and therefore must have been produced from tumour cells disseminated during ICRF 159 administration.
With Triton WR 1339, repeated administration of the compound at 500 mg/kg body weight, or every 4 days at 1250 mg/kg, failed to influence the subcutaneous growth or pulmonary metastases of Sp 1. In contrast, metastases from tumours implanted intratibially, intracerebrally or intramuscularly in the mouse were restricted by similar regimens of chemotherapy (Franchi et al., 1971) and daily injections of only 50 mg/kg inhibited the formation of pulmonary metastases from the Lewis lung carcinoma (Franchi and Garattini, 1971) .
In the one present experiment where Triton was given repeatedly both during subcutaneous growth of epithelioma Spl and after surgical removal of tumour grafts, treatment again failed to suppress metastases and the indication is that pulmonary metastasis was enhanced by the procedure. With a metastasizing hamster lymphoma Cotmore and Carter (1973) found that hepatic metastases were increased by Triton treatment. They interpreted this as due to Triton induced damage of hepatic sinusoidal and Kupffer cells, encouraging trapping or growth of malignant cells in the liver.
In contrast to the present findings, pulmonary metastasis from epithelioma Spl can be restricted by immunotherapeutic methods involving contact of tumour cells with bacillus CalmetteGuerin (B.C.G.) organisms (Baldwin and Pimm, 1973) . Thus, subcutaneous injection of tumour cells in admixture with B.C.G. both retarded local tumour development and reduced the propensity to metastasize. Furthermore, pulmonary metastases appearing after surgical removal of tumour grafts were restricted, and in a proportion of animals completely abolished, by intravenous injection of B.C.G. organisms.
In conclusion, these studies indicate that chemotherapeutic agents having antimetastatic effects in some experimental circumstances may not be generally effective, and may even encourage metastases, although the mechanisms of both suppression and enhancement are complex. Immunotherapeutic methods may be a feasible alternative to chemotherapy for the control of metastases, at least in the lung. 
